1.25

3.85% -0.05

After Hours: 1.30 0.05 +4.00%

Celularity Inc (CELU)

Overview News Price History Option Chain Financials Discussions Forecast

Celularity Inc stock is traded at $1.25, with a volume of 5,835. It is down -3.85% in the last 24 hours and up +2.46% over the past month. Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Previous Close:

$1.30

Open:

$1.2526

24h Volume:

5,835

Relative Volume:

0.04

Market Cap:

$36.05M

Revenue:

$40.58M

Net Income/Loss:

$-80.65M

P/E Ratio:

-0.3753

EPS:

-3.331

Net Cash Flow:

$-8.11M

1W Performance:

-8.76%

1M Performance:

+2.46%

6M Performance:

-42.40%

1Y Performance:

-28.16%

1-Day Range:

$1.2401

$1.30

1-Week Range:

$1.2401

$1.41

52-Week Range:

$1.01

$4.35

Celularity Inc Stock (CELU) Company Profile

Name

Celularity Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(908) 768-2170

Address

170 PARK AVE, FLORHAM PARK

Employee

123

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

CELU's Discussions on Twitter

Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CELU Celularity Inc	1.25	37.49M	40.58M	-80.65M	-8.11M	-3.331
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Celularity Inc Stock (CELU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jun-22-22	Initiated	H.C. Wainwright	Buy
Apr-06-22	Downgrade	Truist	Buy → Hold
Jan-28-22	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	Morgan Stanley	Equal-Weight

View All

Celularity Inc Stock (CELU) Latest News

Apr 15, 2026

Celularity (NASDAQ: CELU) CEO gains shares from RSU vesting - Stock Titan

Apr 15, 2026

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction - The Manila Times

Apr 15, 2026

Apr 13, 2026

Aug Gainers: What is Celularity Inc Equity Warrants market position2026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn

Apr 13, 2026

Trend Recap: Is Celularity Inc stock risky to hold now2026 Summary & Verified Technical Trade Signals - baoquankhu1.vn

Apr 13, 2026

Risk Recap: Is Celularity Inc Equity Warrant a strong candidate for buy and hold2026 Stock Rankings & Momentum Based Trading Signals - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN

Apr 11, 2026

Apr 10, 2026

Gainers Report: Is Celularity Inc Equity Warrant backed by strong institutional buying2026 Catalysts & Short-Term Swing Trade Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 08, 2026

NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction - Bitget

Apr 08, 2026

NEXGEL drops prior financing plan, pushes Celularity update to April 15 - Stock Titan

Apr 08, 2026